In a weaker economy, households tend to keep paying internet bills but steer clear of brand-name goods. What about obesity treatments, which can cost $1,000 a month? The jury is out, but weaker US consumption growth alongside a price war seems bad for Eli Lilly and Novo Nordisk.
Aimee Donnellan is an Associate Editor at various esteemed publications. She specializes in themes related to food and beverages, healthcare, and energy, with a keen focus on capital markets and economic policy. Aimee's work has been featured in Diario EL PAÍS, WAtoday, Regina Leader-Post, HELLENIC SHIPPING NEWS Worldwide, Air Mail, Reuters, Republic World, Reuters Breakingviews, bdnews24.com, and Magzter.








